# Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

> **NCT01260506** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vascular Biogenics Ltd. operating as VBL Therapeutics** · enrollment: 75 (estimated)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** VB-111
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01260506
- **Lead sponsor:** Vascular Biogenics Ltd. operating as VBL Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2015-07-23
- **Final completion:** 2018-12-20
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2020-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01260506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01260506, "Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01260506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*